Growth Hormone–Releasing Hormone: Physiology and What Research Reports

What Is Growth Hormone–Releasing Hormone?

Growth hormone–releasing hormone (GHRH) is a hypothalamic releasing peptide. Neurons in the hypothalamus secrete it into the hypophyseal portal circulation, where it reaches somatotroph cells of the anterior pituitary and binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor coupled to cyclic AMP signalling. The result, in classical endocrine physiology, is synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic production of insulin-like growth factor 1 (IGF-1). Somatostatin opposes this signal, and the balance between the two shapes the pulsatile pattern of GH secretion.

The modern picture is broader than the pituitary alone. A 2020 review of the "GHRH cosmos" reported that GHRH and its receptor are expressed in a range of extrapituitary tissues and that GHRH signalling has been studied for effects that do not depend solely on downstream growth hormone (PMID 32289177). A 2025 review of GHRH and cancer similarly described GHRH receptor expression, including splice variants, in tumour and non-tumour tissues (PMID 39422787).

Where GHRH Is Produced and What It Does

• Source: hypothalamic neurons; release is episodic rather than continuous.
• Primary target: pituitary somatotrophs, via the GHRH receptor.
• Classical output: growth hormone secretion and, downstream, IGF-1.
• Wider distribution: a 2020 review reported receptor expression and signalling in peripheral tissues beyond the pituitary (PMID 32289177).

Extrapituitary sites examined in the literature

Researchers have looked at GHRH receptor biology in several tissue systems. A 2022 study in Endocrinology examined GHRH in endothelial inflammation (PMID 36503995), and a 2023 study examined the alveolar epithelial cell GHRH receptor in alveolar epithelial inflammation (PMID 37584484). A study published in The Korean Journal of Internal Medicine investigated the effect of GHRH on chondrocytes in the setting of osteoarthritis (PMID 31875669), and a 2020 report in Endocrine placed GHRH within the unfolded protein response, the cellular stress pathway triggered by misfolded proteins (PMID 31960289).

How GHRH Is Measured and Studied

Because circulating GHRH is released in pulses and is largely consumed locally in the portal circulation, most of the published work relies on indirect or laboratory approaches rather than simple blood levels:

1. Receptor pharmacology. Agonist and antagonist analogs of GHRH are applied to cells or animals to see which effects depend on the receptor; a 2019 study used a GHRH receptor antagonist to examine lung inflammation and fibrosis after bleomycin exposure (PMID 31392398).
2. Cell and tissue models. Isolated chondrocytes, endothelial cells, alveolar epithelial cells and immune cells have each been used to test GHRH signalling directly (PMID 31875669, PMID 36503995).
3. Comparative genetics. Cloning and functional characterisation in other species clarifies how conserved the system is; a 2021 paper cloned and functionally characterised GHRH in the fish Mastacembelus armatus (PMID 33118088).
4. Analytical chemistry. A 2021 review in Drug Testing and Analysis summarised advances in the detection of synthetic GHRH analogs, a task relevant to anti-doping laboratories (PMID 34665524).

What the Literature Reports

Two directions in the same field

One strand of this literature explores GHRH agonism — for example, the 2020 study that reported GHRH enhanced the reparative performance of endothelial progenitor cells in ischemia models (PMID 31506908). Another strand explores antagonism, where blocking the receptor is the intervention, as in the bleomycin lung study (PMID 31392398) and in the oncology review describing antagonist development (PMID 39422787). Readers encountering GHRH in a research summary therefore need to check which direction a given paper tested; the two produce opposite predictions.

Safety Signals in GHRH Research: What Studies Report

The verified literature summarised here is largely mechanistic and preclinical, and these papers did not report human adverse-event tables. Some findings are nonetheless framed by their authors as biologically double-edged: the 2023 immunology study reported that GHRH signalling promoted Th17 differentiation and autoimmune inflammation, an outcome that would not be desirable in an inflammatory disease context (PMID 37280225). Similarly, the 2025 cancer review discussed GHRH receptor expression in tumours as a rationale for antagonist rather than agonist approaches (PMID 39422787). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or treatment decision.

Why the Term Matters to Peptide Readers

GHRH is the reference point for an entire family of synthetic peptides described in the literature as GHRH analogs — molecules built to resemble the natural hormone or to block its receptor. That is why the term appears in anti-doping chemistry: the 2021 analytical review was written specifically because synthetic GHRH analogs required detection methods in sport drug testing (PMID 34665524). Understanding the parent hormone — where it is made, what receptor it uses, and what tissues express that receptor — makes the analog literature easier to read.

Limitations of the Current Evidence

• Much of the cited work is in cells or animals; the fish cloning study, for example, characterised GHRH in a non-mammalian species (PMID 33118088).
• Reviews such as the 2016 diabetes review and the 2020 overview synthesise heterogeneous studies rather than reporting a single controlled experiment (PMID 27777568, PMID 32289177).
• Effects attributed to GHRH in one tissue model do not automatically transfer to another tissue, species or clinical population.

References

• A glimpse at growth hormone-releasing hormone cosmos (Clinical and Experimental Pharmacology & Physiology, 2020)
• Growth Hormone-Releasing Hormone in Diabetes (Frontiers in Endocrinology, 2016)
• Growth hormone releasing hormone in the unfolded protein response context (Endocrine, 2020)
• Effect of growth hormone releasing hormone on chondrocytes of osteoarthritis (The Korean Journal of Internal Medicine, 2022)
• Growth hormone releasing hormone signaling promotes Th17 cell differentiation and autoimmune inflammation (Nature Communications, 2023)
• Alveolar epithelial cell growth hormone releasing hormone receptor in alveolar epithelial inflammation (Experimental Lung Research, 2023)
• Growth hormone-releasing hormone and cancer (Reviews in Endocrine & Metabolic Disorders, 2025)
• Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin (Lung, 2019)
• Molecular cloning and functional characterization of growth hormone-releasing hormone in Mastacembelus armatus (Fish Physiology and Biochemistry, 2021)
• Growth Hormone-Releasing Hormone in Endothelial Inflammation (Endocrinology, 2022)
• Growth hormone-releasing hormone promotes therapeutic effects of peripheral blood endothelial progenitor cells in ischemic repair (Journal of Endocrinological Investigation, 2020)
• Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Testing and Analysis, 2021)